What does AnGes, Inc. do?

AnGes, Inc. (4563.T) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 4563.T's market cap?

AnGes, Inc. (4563.T) has a market capitalization of approximately $15.83 billion, as of August 28, 2026, based on the most recent share price and shares outstanding.

Does 4563.T pay a dividend?

No — AnGes, Inc. (4563.T) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 4563.T profitable?

AnGes, Inc. (4563.T) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

4563.T

AnGes, Inc.

JPX·Biotechnology · Healthcare

¥40¥1+2.56%

Market cap¥15.83B·Aug 28 6:30 AM UTC

Price Chart

¥40+¥1.00 (+2.56%)today

−95.04%CAGR −45.19%

Select date range

FromTo

Sep 25, 2002Aug 28, 2021 → Aug 28, 2026· 5.0 yrsAug 28, 2026

Key Metrics

4563.T does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 6

Last Report DateAug 14

Reported vs Estimate−¥4.11

Earnings Surprise—

FinancialsFinancials Tab

Revenue¥961.90M

Net Income−¥3.87B

Net Margin−402.5%

Operating Cash Flow¥0.00

Capital Expenditures¥0.00

Free Cash Flow¥0.00

Return on Equity−1,882.3%

Return on Invested Capital−170.9%

Net Debt¥427.07M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 4563.T and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 4563.T's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4563.T and 80,000+ other tickers.

About AnGes, Inc.

AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmid, an innovative gene therapy designed to address critical limb ischemia, a severe circulatory condition impacting the legs. The company's diverse pipeline also includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine formulated to suppress inflammation for various ailments, including low back pain. Furthermore, AnGes is actively developing…

CEO: Ei Yamada
Sector: Healthcare
Industry: Biotechnology
Exchange: JPX
Employees: 56
Website: www.anges.co.jp

Peers

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 4563.T

What does AnGes, Inc. do?: AnGes, Inc. (4563.T) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 4563.T's market cap?: AnGes, Inc. (4563.T) has a market capitalization of approximately $15.83 billion, as of August 28, 2026, based on the most recent share price and shares outstanding.
Does 4563.T pay a dividend?: No — AnGes, Inc. (4563.T) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 4563.T profitable?: AnGes, Inc. (4563.T) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.